PDCD1 and colorectal carcinoma: Notably, a combination of regorafenib and nivolumab (anti-PD-1) in patients with advanced CRC yielded a 29% response rate, a reduced FoxP3hiCD45RA-Tregs fraction, a manageable safety profile, and an anti-tumor effect [286].